SCHEMBL3015186

SCHEMBL3015186

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(c3nc(Cc4cc(F)cc(F)c4)cs3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 12/20 0.52
ALDH1A1 P00352 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
GBA1 P04062 2/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007296 0.94 HSD11B1 (0.48) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3010593 0.90 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3011891 0.89 HSD11B1 (0.51) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3015421 0.89 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3005421 0.89 HSD11B1 (0.48) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3012994 0.89 HSD11B1 (0.52) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3000583 0.87 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2L3MBTL1KMT2AUSP2
SCHEMBL3008276 0.87 HSD11B1 (0.52) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3007387 0.87 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL3015775 0.87 HSD11B1 (0.48) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD11B1 1034/4885ALDH1A1 3510/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.